---
title: "NextCure Drops 8% in Trading Amid Shareholder Probe of Merger Deal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292921286.md"
description: "NextCure (NXTC) shares fell 8% to $6.14 amid shareholder lawsuit over dilutive merger with Avere Therapeutics."
datetime: "2026-07-16T14:31:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292921286.md)
  - [en](https://longbridge.com/en/news/292921286.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292921286.md)
generator: "portal-rs"
---

# NextCure Drops 8% in Trading Amid Shareholder Probe of Merger Deal

NextCure(NXTC.US) 盘中跌超 8%，现报 6.14 美元。

公司近日宣布与 Avere Therapeutics 进行全股票合并，合并后实体将以 Avere Therapeutics(AVRX) 名义在纳斯达克运营。根据协议，Avere 股东将持有新公司约 98-99% 股份，NextCure 原有股东仅获得 1-2% 股份及或有价值权。

多家股东权利律师事务所已对此次合并交易展开调查，指控该交易严重稀释原有股东权益，并关注董事会信义义务及是否存在限制竞争性收购的不合理条款。交易同时涉及 3.2 亿美元私募融资，用于资助 AVR-001 的 2b/3 期临床试验。

此前一个交易日，该股在盘前交易曾下跌 21.13%，夜盘交易中亦跌 5.43%，股价连续承压。

### Related Stocks

- [NXTC.US](https://longbridge.com/en/quote/NXTC.US.md)

## Related News & Research

- [Major Investor Makes Bold Move on NextCure Shares](https://longbridge.com/en/news/294757721.md)
- [ADAR1 Capital Management reports NextCure common share purchase worth $3.59 million](https://longbridge.com/en/news/294742349.md)
- [BUZZ-NextCure jumps on merger with Avere, $320 million financing](https://longbridge.com/en/news/292605938.md)
- [Hansoh-backed Avere agrees to merge with NextCure in all-stock deal](https://longbridge.com/en/news/292602916.md)
- [NextCure Q2 net loss narrows on lower expenses](https://longbridge.com/en/news/295138619.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**